Mark Plavsic's Insider Trades & SAST Disclosures
Mark Plavsic's most recent trade in Aura Biosciences Inc was a trade of 2,151 Common Stock done at an average price of $7.7 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Plavsic.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 18 Feb 2025 | 2,151 | 209,456 | - | 7.7 | 16,670 | Common Stock |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 90,475 | 211,607 | - | 0 | Common Stock | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 59,525 | 59,525 | - | - | Stock Option (Right to Buy) | |
| Aura Biosciences Inc | Mark Plavsic | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 9.85 per share. | 16 Oct 2024 | 7,383 | 121,132 | - | 9.9 | 72,723 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 3,418 | 123,705 (0%) | 0% | 5.2 | 17,910 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Sale of securities on an exchange or to another person at price $ 24.61 per share. | 05 Jul 2022 | 3,719 | 127,123 (0%) | 0% | 24.6 | 91,525 | Common Stock |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 53,058 | 53,058 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 33,302 | 130,842 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 59,540 | 97,540 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 38,000 | 38,000 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Mark Plavsic | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges